Brain Biomarkers Market by Biomarker Type (Genetic, Imaging, Metabolite), Disease Indication (Alzheimer's Disease, Epilepsy, Multiple Sclerosis), Sample Type, Technology, End User - Global Forecast 2025-2032
Description
The Brain Biomarkers Market was valued at USD 10.54 billion in 2024 and is projected to grow to USD 12.50 billion in 2025, with a CAGR of 18.41%, reaching USD 40.74 billion by 2032.
A strategic orientation to brain biomarkers that synthesizes scientific advances, clinical translation priorities, and stakeholder convergence shaping immediate research and care pathways
Brain biomarkers occupy a rapidly maturing intersection of neuroscience, molecular diagnostics, and clinical care, offering actionable signals that bridge discovery science and patient-level decision-making. Advances in molecular profiling, imaging modalities and analytic platforms now permit earlier, more specific detection of neurologic disease biology, while improved sample accessibility and processing have broadened the contexts in which biomarkers can be deployed. This introduction frames the subsequent analysis by highlighting the scientific drivers, translational milestones, and commercial dynamics that together define the biomarker landscape today.
Across academic centers, diagnostic labs and industry pipelines, stakeholders are converging around a shared set of priorities: reproducibility, clinical validity, and clear pathways to utility. As a result, collaborations between technology specialists and clinical researchers have intensified, accelerating assay standardization and regulatory engagement. This section orients readers to the core themes-technological convergence, disease-focused application, and evolving stakeholder roles-that will be examined in depth throughout the report.
How technological convergence and rising clinical evidence expectations are fundamentally altering the development and adoption pathways for brain biomarker solutions
The landscape for brain biomarkers is undergoing transformative shifts driven by integrated technological innovation and shifting clinical expectations. Next-generation sequencing and high-resolution mass spectrometry have elevated sensitivity and multiplexing capacity, while advanced imaging protocols and AI-enabled analytics have redefined how structural and functional signals are interpreted for diagnostic and prognostic use. Together, these capabilities have reduced the technical barriers to multi-modal biomarker integration, making composite diagnostic frameworks increasingly viable.
Concurrently, clinical adoption patterns are evolving: clinicians demand biomarkers that demonstrate clear incremental utility in care pathways, not only analytical performance. Payers and regulators are emphasizing evidence of clinical actionability, encouraging prospective validation studies and health-economic assessments. This confluence of technical progress and pragmatic evidence requirements is shifting investment toward assays and platforms that can deliver reproducible, clinically meaningful results and be integrated into established workflows across hospitals, diagnostic laboratories and research networks.
Assessment of how US tariff measures enacted in 2025 have reshaped supply chain resilience, sourcing strategies, and operational planning across the brain biomarker ecosystem
The introduction of targeted tariffs in the United States during 2025 has produced a set of cumulative impacts that ripple across supply chains, sourcing decisions and cost structures relevant to brain biomarker development and deployment. Tariff-related cost increases have prompted manufacturers and laboratories to reassess sourcing strategies for reagents, instrumentation and assay consumables, which in turn has affected procurement timelines and vendor negotiations. Faced with higher landed costs for certain imported components, organizations have pursued supplier diversification, local contracting, or demand consolidation to mitigate expense volatility and preserve operational throughput.
Beyond procurement, the tariffs have influenced global collaboration patterns. International partnerships that rely on cross-border shipment of biological materials, sequencing flow cells or specialized reagents have encountered tighter cost and timing constraints, necessitating revised contractual terms and contingency plans. In parallel, some companies have accelerated regional manufacturing or localized assembly to shield critical workflows from sustained tariff exposure. While sensitivity to these policy-driven inputs varies by organization and product complexity, the collective response emphasizes resilience: entities are prioritizing supply-chain transparency, long-term supplier relationships and flexible sourcing models to sustain clinical validation programs and maintain timelines for research and diagnostic services.
Detailed segmentation analysis illuminating where biomarker types, disease targets, sample matrices, technologies and end users converge to enable differentiated clinical and commercial opportunities
Key segmentation insights reveal where scientific opportunity and commercial readiness align across biomarker types, disease indications, sample matrices, technologies and end users. In biomarker taxonomy, genetic markers-including gene expression profiles, microRNA signatures and single nucleotide polymorphisms-offer high specificity for molecular subtyping and are increasingly paired with imaging and proteomic data to refine diagnostic phenotypes. Imaging markers derived from CT, MRI and PET continue to deliver indispensable structural and functional context, and when integrated with molecular readouts they strengthen diagnostic confidence and longitudinal monitoring capabilities. Metabolite-based markers, spanning lipid metabolites and small molecule metabolites, provide complementary information on cellular metabolism and are well suited to fluid-based surveillance. Protein biomarkers measured in cerebrospinal fluid, plasma and saliva capture pathophysiologic processes and present varied trade-offs between invasiveness and analytical robustness.
Disease-focused segmentation underscores differentiated development trajectories. Biomarkers for Alzheimer’s disease have concentrated on both established protein analytes and multi-modal signatures to address diagnostic complexity, while epilepsy biomarker efforts emphasize electrophysiologic correlates augmented by targeted molecular assays to improve seizure risk stratification. Multiple sclerosis initiatives leverage immunologically oriented protein and metabolite indicators to monitor inflammatory activity, whereas Parkinson’s disease research integrates genetic and protein markers to distinguish subtypes and progression patterns. Stroke biomarker development prioritizes rapid, accessible sample types to support acute decision-making. Regarding sample sources, blood-derived matrices, including plasma and serum, provide the most scalable clinical pathway, whereas cerebrospinal fluid remains the reference for certain central nervous system–specific markers; saliva and urine offer noninvasive alternatives for screening or longitudinal follow-up. Technology segmentation highlights the complementary roles of chromatography (HPLC and UHPLC) and mass spectrometry (GC-MS and LC-MS) for targeted metabolite and protein quantitation, immunoassays such as ELISA and lateral flow for scalable protein detection, and high-throughput molecular platforms including next-generation sequencing (targeted and whole-genome) and PCR variants (digital PCR and qPCR) for genetic interrogation. Finally, end-user segmentation reveals distinct adoption dynamics: contract research organizations and diagnostic laboratories concentrate on assay development and throughput, hospitals emphasize clinical integration and workflow compatibility, pharmaceutical companies pursue biomarkers for trial enrichment and companion diagnostics, and research institutes continue to drive fundamental discovery and validation studies.
How regional regulatory frameworks, infrastructure strengths and investment priorities across the Americas, Europe Middle East & Africa and Asia-Pacific determine the pace and pattern of biomarker adoption
Regional dynamics shape how biomarkers are developed, validated and adopted, reflecting differing regulatory frameworks, infrastructure strengths and investment patterns across geographies. In the Americas, academic-clinical partnerships, robust private investment and established laboratory networks create an environment conducive to rapid translational work and multi-center validation studies. This region also exhibits a strong market for integrated imaging–molecular diagnostics, supported by high-capacity imaging facilities and genomic sequencing centers, which facilitates comprehensive protocol testing and iterative clinical pathway refinement.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts and cross-border clinical consortia often enable multinational validation programs, but variable reimbursement environments and infrastructure disparities can slow uniform adoption. Targeted investments in reference laboratories and center-of-excellence models have nonetheless supported uptake of specialized assays and advanced imaging techniques. In Asia-Pacific, high-volume clinical systems, rapidly expanding diagnostic networks and growing domestic manufacturing capabilities are accelerating scale-up of validated tests and localized production of key reagents and instruments. This region is notable for agile public–private partnerships and focused initiatives to integrate biomarkers into national research priorities, creating fertile ground for both innovation and expedited real-world implementation.
Competitive dynamics and collaborative strategies among instrument providers, diagnostic innovators, contract research organizations, and pharmaceutical partners that accelerate validation and deployment
Leading companies and emerging specialists are shaping the brain biomarker ecosystem through differentiated capabilities across assay development, platform engineering and clinical validation. Established instrument and reagent providers sustain the throughput and analytical precision that underpin many assays, while a new wave of technology-focused firms delivers high-sensitivity platforms and integrated analytics that enable multi-analyte measurement and data harmonization. Strategic collaborations between diagnostic innovators, academic centers and clinical research organizations are increasingly common, combining validation capacity with pathway design expertise to accelerate clinical acceptance.
At the same time, contract research organizations and specialty laboratories play pivotal roles by offering scalable assay development, regulatory-compliant testing environments and access to diverse sample sets needed for robust validation. Pharmaceutical companies continue to invest in biomarker programs that support patient stratification and trial optimization, frequently partnering with platform providers to develop companion diagnostics. This multi-actor ecosystem demonstrates a continuum from discovery to deployment, where commercial differentiation depends on validated clinical utility, cost-effective scalability and the ability to integrate biomarker outputs into clinical decision support systems.
Actionable strategic priorities for industry leaders that align robust multi-modal validation, supply chain resilience, collaborative evidence generation, and payer engagement to drive adoption
Industry leaders should adopt actionable strategies that balance scientific rigor with operational scalability to capture durable value. First, prioritize multi-modal validation programs that combine genetic, proteomic, metabolite and imaging signals to establish robust clinical performance across intended-use populations. Such integrated evidence strengthens payer and regulatory conversations and increases clinical confidence during adoption. Second, invest in supply-chain transparency and regional manufacturing or assembly capabilities to dampen exposure to policy-driven cost shocks and maintain continuity for critical reagents and instruments.
Third, cultivate strategic alliances across hospitals, diagnostic laboratories and contract research providers to access clinically annotated sample cohorts and real-world workflows early in development, enabling smoother clinical integration. Fourth, deploy adaptable data infrastructure and standardized reporting frameworks so biomarker outputs can be interpreted consistently across institutions; this will support multi-site studies and accelerate acceptance by clinicians and payers. Finally, engage proactively with regulators and health-technology assessment bodies to align validation endpoints with decision-making criteria, while also designing health-economic analyses that demonstrate tangible improvements in care pathways and resource utilization.
A robust, transparent research methodology combining literature synthesis, technology appraisals, regulatory guidance and expert engagement to ground actionable insights and recommendations
The methodological approach underpinning this analysis synthesizes publicly available scientific literature, regulatory guidance, technology white papers and primary qualitative inputs from subject-matter experts across clinical, academic and industry settings. Evidence synthesis emphasized peer-reviewed studies that evaluated analytical performance and clinical associations, while technical evaluations relied on comparative platform assessments and validated protocol descriptions. Stakeholder interviews provided context on adoption barriers, operational constraints and strategic priorities that influence translational progress.
To ensure rigor, the approach triangulated findings from diverse sources and prioritized reproducibility and methodological transparency. Comparative technology appraisals considered analytical sensitivity, specificity, throughput and compatibility with clinical workflows. Where regulatory considerations were material, guidance documents and precedent approvals informed likely pathways to clinical use. This combined methodology supports balanced, actionable insights while recognizing that ongoing primary studies and prospective clinical validation remain essential to confirm the clinical utility of specific biomarker applications.
Concluding synthesis emphasizing the transition from isolated biomarker signals to integrated, validated solutions that enable earlier diagnosis, stratification and clinical utility
In summary, brain biomarkers are transitioning from isolated signals to integrated diagnostic and monitoring solutions that can materially influence clinical pathways. Scientific advances in genetic, proteomic, metabolite and imaging technologies are enabling richer, multi-dimensional characterizations of neurologic disease, while pragmatic pressures-clinical utility requirements, supply-chain resilience and regional regulatory frameworks-shape which solutions progress to widespread adoption. The report highlights how targeted investments in validation, interoperability and regional manufacturing can reduce adoption friction and accelerate practical deployment.
Looking ahead, stakeholders that combine multi-modal evidence generation with proactive payer and regulatory engagement will be best positioned to translate technical innovation into clinical practice. Continued collaboration across academic centers, diagnostic laboratories, hospitals and commercial developers will remain essential to realize the promise of biomarkers for earlier diagnosis, improved stratification and more efficient therapeutic development. The conclusion emphasizes the imperative to align high-quality evidence generation with operational readiness to support sustainable clinical integration.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic orientation to brain biomarkers that synthesizes scientific advances, clinical translation priorities, and stakeholder convergence shaping immediate research and care pathways
Brain biomarkers occupy a rapidly maturing intersection of neuroscience, molecular diagnostics, and clinical care, offering actionable signals that bridge discovery science and patient-level decision-making. Advances in molecular profiling, imaging modalities and analytic platforms now permit earlier, more specific detection of neurologic disease biology, while improved sample accessibility and processing have broadened the contexts in which biomarkers can be deployed. This introduction frames the subsequent analysis by highlighting the scientific drivers, translational milestones, and commercial dynamics that together define the biomarker landscape today.
Across academic centers, diagnostic labs and industry pipelines, stakeholders are converging around a shared set of priorities: reproducibility, clinical validity, and clear pathways to utility. As a result, collaborations between technology specialists and clinical researchers have intensified, accelerating assay standardization and regulatory engagement. This section orients readers to the core themes-technological convergence, disease-focused application, and evolving stakeholder roles-that will be examined in depth throughout the report.
How technological convergence and rising clinical evidence expectations are fundamentally altering the development and adoption pathways for brain biomarker solutions
The landscape for brain biomarkers is undergoing transformative shifts driven by integrated technological innovation and shifting clinical expectations. Next-generation sequencing and high-resolution mass spectrometry have elevated sensitivity and multiplexing capacity, while advanced imaging protocols and AI-enabled analytics have redefined how structural and functional signals are interpreted for diagnostic and prognostic use. Together, these capabilities have reduced the technical barriers to multi-modal biomarker integration, making composite diagnostic frameworks increasingly viable.
Concurrently, clinical adoption patterns are evolving: clinicians demand biomarkers that demonstrate clear incremental utility in care pathways, not only analytical performance. Payers and regulators are emphasizing evidence of clinical actionability, encouraging prospective validation studies and health-economic assessments. This confluence of technical progress and pragmatic evidence requirements is shifting investment toward assays and platforms that can deliver reproducible, clinically meaningful results and be integrated into established workflows across hospitals, diagnostic laboratories and research networks.
Assessment of how US tariff measures enacted in 2025 have reshaped supply chain resilience, sourcing strategies, and operational planning across the brain biomarker ecosystem
The introduction of targeted tariffs in the United States during 2025 has produced a set of cumulative impacts that ripple across supply chains, sourcing decisions and cost structures relevant to brain biomarker development and deployment. Tariff-related cost increases have prompted manufacturers and laboratories to reassess sourcing strategies for reagents, instrumentation and assay consumables, which in turn has affected procurement timelines and vendor negotiations. Faced with higher landed costs for certain imported components, organizations have pursued supplier diversification, local contracting, or demand consolidation to mitigate expense volatility and preserve operational throughput.
Beyond procurement, the tariffs have influenced global collaboration patterns. International partnerships that rely on cross-border shipment of biological materials, sequencing flow cells or specialized reagents have encountered tighter cost and timing constraints, necessitating revised contractual terms and contingency plans. In parallel, some companies have accelerated regional manufacturing or localized assembly to shield critical workflows from sustained tariff exposure. While sensitivity to these policy-driven inputs varies by organization and product complexity, the collective response emphasizes resilience: entities are prioritizing supply-chain transparency, long-term supplier relationships and flexible sourcing models to sustain clinical validation programs and maintain timelines for research and diagnostic services.
Detailed segmentation analysis illuminating where biomarker types, disease targets, sample matrices, technologies and end users converge to enable differentiated clinical and commercial opportunities
Key segmentation insights reveal where scientific opportunity and commercial readiness align across biomarker types, disease indications, sample matrices, technologies and end users. In biomarker taxonomy, genetic markers-including gene expression profiles, microRNA signatures and single nucleotide polymorphisms-offer high specificity for molecular subtyping and are increasingly paired with imaging and proteomic data to refine diagnostic phenotypes. Imaging markers derived from CT, MRI and PET continue to deliver indispensable structural and functional context, and when integrated with molecular readouts they strengthen diagnostic confidence and longitudinal monitoring capabilities. Metabolite-based markers, spanning lipid metabolites and small molecule metabolites, provide complementary information on cellular metabolism and are well suited to fluid-based surveillance. Protein biomarkers measured in cerebrospinal fluid, plasma and saliva capture pathophysiologic processes and present varied trade-offs between invasiveness and analytical robustness.
Disease-focused segmentation underscores differentiated development trajectories. Biomarkers for Alzheimer’s disease have concentrated on both established protein analytes and multi-modal signatures to address diagnostic complexity, while epilepsy biomarker efforts emphasize electrophysiologic correlates augmented by targeted molecular assays to improve seizure risk stratification. Multiple sclerosis initiatives leverage immunologically oriented protein and metabolite indicators to monitor inflammatory activity, whereas Parkinson’s disease research integrates genetic and protein markers to distinguish subtypes and progression patterns. Stroke biomarker development prioritizes rapid, accessible sample types to support acute decision-making. Regarding sample sources, blood-derived matrices, including plasma and serum, provide the most scalable clinical pathway, whereas cerebrospinal fluid remains the reference for certain central nervous system–specific markers; saliva and urine offer noninvasive alternatives for screening or longitudinal follow-up. Technology segmentation highlights the complementary roles of chromatography (HPLC and UHPLC) and mass spectrometry (GC-MS and LC-MS) for targeted metabolite and protein quantitation, immunoassays such as ELISA and lateral flow for scalable protein detection, and high-throughput molecular platforms including next-generation sequencing (targeted and whole-genome) and PCR variants (digital PCR and qPCR) for genetic interrogation. Finally, end-user segmentation reveals distinct adoption dynamics: contract research organizations and diagnostic laboratories concentrate on assay development and throughput, hospitals emphasize clinical integration and workflow compatibility, pharmaceutical companies pursue biomarkers for trial enrichment and companion diagnostics, and research institutes continue to drive fundamental discovery and validation studies.
How regional regulatory frameworks, infrastructure strengths and investment priorities across the Americas, Europe Middle East & Africa and Asia-Pacific determine the pace and pattern of biomarker adoption
Regional dynamics shape how biomarkers are developed, validated and adopted, reflecting differing regulatory frameworks, infrastructure strengths and investment patterns across geographies. In the Americas, academic-clinical partnerships, robust private investment and established laboratory networks create an environment conducive to rapid translational work and multi-center validation studies. This region also exhibits a strong market for integrated imaging–molecular diagnostics, supported by high-capacity imaging facilities and genomic sequencing centers, which facilitates comprehensive protocol testing and iterative clinical pathway refinement.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts and cross-border clinical consortia often enable multinational validation programs, but variable reimbursement environments and infrastructure disparities can slow uniform adoption. Targeted investments in reference laboratories and center-of-excellence models have nonetheless supported uptake of specialized assays and advanced imaging techniques. In Asia-Pacific, high-volume clinical systems, rapidly expanding diagnostic networks and growing domestic manufacturing capabilities are accelerating scale-up of validated tests and localized production of key reagents and instruments. This region is notable for agile public–private partnerships and focused initiatives to integrate biomarkers into national research priorities, creating fertile ground for both innovation and expedited real-world implementation.
Competitive dynamics and collaborative strategies among instrument providers, diagnostic innovators, contract research organizations, and pharmaceutical partners that accelerate validation and deployment
Leading companies and emerging specialists are shaping the brain biomarker ecosystem through differentiated capabilities across assay development, platform engineering and clinical validation. Established instrument and reagent providers sustain the throughput and analytical precision that underpin many assays, while a new wave of technology-focused firms delivers high-sensitivity platforms and integrated analytics that enable multi-analyte measurement and data harmonization. Strategic collaborations between diagnostic innovators, academic centers and clinical research organizations are increasingly common, combining validation capacity with pathway design expertise to accelerate clinical acceptance.
At the same time, contract research organizations and specialty laboratories play pivotal roles by offering scalable assay development, regulatory-compliant testing environments and access to diverse sample sets needed for robust validation. Pharmaceutical companies continue to invest in biomarker programs that support patient stratification and trial optimization, frequently partnering with platform providers to develop companion diagnostics. This multi-actor ecosystem demonstrates a continuum from discovery to deployment, where commercial differentiation depends on validated clinical utility, cost-effective scalability and the ability to integrate biomarker outputs into clinical decision support systems.
Actionable strategic priorities for industry leaders that align robust multi-modal validation, supply chain resilience, collaborative evidence generation, and payer engagement to drive adoption
Industry leaders should adopt actionable strategies that balance scientific rigor with operational scalability to capture durable value. First, prioritize multi-modal validation programs that combine genetic, proteomic, metabolite and imaging signals to establish robust clinical performance across intended-use populations. Such integrated evidence strengthens payer and regulatory conversations and increases clinical confidence during adoption. Second, invest in supply-chain transparency and regional manufacturing or assembly capabilities to dampen exposure to policy-driven cost shocks and maintain continuity for critical reagents and instruments.
Third, cultivate strategic alliances across hospitals, diagnostic laboratories and contract research providers to access clinically annotated sample cohorts and real-world workflows early in development, enabling smoother clinical integration. Fourth, deploy adaptable data infrastructure and standardized reporting frameworks so biomarker outputs can be interpreted consistently across institutions; this will support multi-site studies and accelerate acceptance by clinicians and payers. Finally, engage proactively with regulators and health-technology assessment bodies to align validation endpoints with decision-making criteria, while also designing health-economic analyses that demonstrate tangible improvements in care pathways and resource utilization.
A robust, transparent research methodology combining literature synthesis, technology appraisals, regulatory guidance and expert engagement to ground actionable insights and recommendations
The methodological approach underpinning this analysis synthesizes publicly available scientific literature, regulatory guidance, technology white papers and primary qualitative inputs from subject-matter experts across clinical, academic and industry settings. Evidence synthesis emphasized peer-reviewed studies that evaluated analytical performance and clinical associations, while technical evaluations relied on comparative platform assessments and validated protocol descriptions. Stakeholder interviews provided context on adoption barriers, operational constraints and strategic priorities that influence translational progress.
To ensure rigor, the approach triangulated findings from diverse sources and prioritized reproducibility and methodological transparency. Comparative technology appraisals considered analytical sensitivity, specificity, throughput and compatibility with clinical workflows. Where regulatory considerations were material, guidance documents and precedent approvals informed likely pathways to clinical use. This combined methodology supports balanced, actionable insights while recognizing that ongoing primary studies and prospective clinical validation remain essential to confirm the clinical utility of specific biomarker applications.
Concluding synthesis emphasizing the transition from isolated biomarker signals to integrated, validated solutions that enable earlier diagnosis, stratification and clinical utility
In summary, brain biomarkers are transitioning from isolated signals to integrated diagnostic and monitoring solutions that can materially influence clinical pathways. Scientific advances in genetic, proteomic, metabolite and imaging technologies are enabling richer, multi-dimensional characterizations of neurologic disease, while pragmatic pressures-clinical utility requirements, supply-chain resilience and regional regulatory frameworks-shape which solutions progress to widespread adoption. The report highlights how targeted investments in validation, interoperability and regional manufacturing can reduce adoption friction and accelerate practical deployment.
Looking ahead, stakeholders that combine multi-modal evidence generation with proactive payer and regulatory engagement will be best positioned to translate technical innovation into clinical practice. Continued collaboration across academic centers, diagnostic laboratories, hospitals and commercial developers will remain essential to realize the promise of biomarkers for earlier diagnosis, improved stratification and more efficient therapeutic development. The conclusion emphasizes the imperative to align high-quality evidence generation with operational readiness to support sustainable clinical integration.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of multiomics data with machine learning for precision brain biomarker profiling in Alzheimer’s disease
- 5.2. Commercialization of ultra-sensitive immunoassays enabling early detection of Parkinson’s disease pathology from plasma samples
- 5.3. Development of digital biomarker platforms using wearable EEG and neuroimaging for real-time cognitive monitoring
- 5.4. Standardization initiatives for cerebrospinal fluid tau and amyloid beta quantification across global clinical laboratories
- 5.5. Growth of companion diagnostic biomarker tests for targeted therapies in multiple sclerosis and glioblastoma treatment protocols
- 5.6. Utilization of exosomal microRNA signatures in blood as non-invasive indicators of traumatic brain injury severity and prognosis
- 5.7. Expansion of point-of-care biomarker testing devices for rapid stroke subtype differentiation in emergency care settings
- 5.8. Integration of AI-driven image analysis to quantify PET-based neuroinflammation biomarkers in clinical trials
- 5.9. Emergence of normative brain network connectivity metrics as predictive biomarkers for psychiatric disorder onset and progression
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Brain Biomarkers Market, by Biomarker Type
- 8.1. Genetic
- 8.1.1. Gene Expression Markers
- 8.1.2. Mirna Markers
- 8.1.3. Snp Markers
- 8.2. Imaging
- 8.2.1. CT
- 8.2.2. MRI
- 8.2.3. PET
- 8.3. Metabolite
- 8.3.1. Lipid Metabolites
- 8.3.2. Small Molecule Metabolites
- 8.4. Protein
- 8.4.1. CSF Proteins
- 8.4.2. Plasma Proteins
- 8.4.3. Saliva Proteins
- 9. Brain Biomarkers Market, by Disease Indication
- 9.1. Alzheimer's Disease
- 9.2. Epilepsy
- 9.3. Multiple Sclerosis
- 9.4. Parkinson's Disease
- 9.5. Stroke
- 10. Brain Biomarkers Market, by Sample Type
- 10.1. Blood
- 10.1.1. Plasma
- 10.1.2. Serum
- 10.2. Cerebrospinal Fluid
- 10.3. Saliva
- 10.4. Urine
- 11. Brain Biomarkers Market, by Technology
- 11.1. Chromatography
- 11.2. Immunoassay
- 11.3. Mass Spectrometry
- 11.4. Next Generation Sequencing
- 11.5. PCR
- 12. Brain Biomarkers Market, by End User
- 12.1. Contract Research Organizations
- 12.2. Diagnostic Laboratories
- 12.3. Hospitals
- 12.4. Pharmaceutical Companies
- 12.5. Research Institutes
- 13. Brain Biomarkers Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Brain Biomarkers Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Brain Biomarkers Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Roche Holding AG
- 16.3.2. Abbott Laboratories
- 16.3.3. Quanterix Corporation
- 16.3.4. F. Hoffmann-La Roche AG
- 16.3.5. Eli Lilly and Company
- 16.3.6. Biogen Inc.
- 16.3.7. Fujirebio Diagnostics, Inc.
- 16.3.8. Merck KGaA
- 16.3.9. Siemens Healthineers AG
- 16.3.10. Banyan Biomarkers, Inc.
- 16.3.11. C2N Diagnostics, LLC
- 16.3.12. ADx NeuroSciences NV
- 16.3.13. Janssen Pharmaceuticals, Inc.
- 16.3.14. Novartis AG
- 16.3.15. Quretec Ltd.
- 16.3.16. DiaSorin S.p.A.
- 16.3.17. Mesoscale Discovery, LLC
- 16.3.18. Amprion, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
